Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Thoughts on the RAMES study in mesothelioma

Sanjay Popat • 11 Jun 2020
ASCO 2020
Lung Cancer Mesothelioma Carboplatin Cisplatin Durvalumab Ipilimumab Nivolumab Pemetrexed
CheckMate 743 RAMES

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, reviews data from the Phase II RAMES study (NCT03560973) which evaluated the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in patients with relapsed, advanced mesothelioma. He also discusses the next steps for this regimen in light of the impending CheckMate 743 data (NCT02899299). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology),

More from Sanjay Popat

2:33
Reflecting on BTOG 2024: networking and multidisciplinary collaboration
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals